Research programme: anti-factor XI monoclonal antibodies - Novartis

Drug Profile

Research programme: anti-factor XI monoclonal antibodies - Novartis

Alternative Names: NOV 1090; NOV 1401

Latest Information Update: 14 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Monoclonal antibodies
  • Mechanism of Action Factor XI inhibitors; Factor XIa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Thrombosis

Most Recent Events

  • 29 Dec 2016 Preclinical trials in Thrombosis in Switzerland (Parenteral) before December 2016
  • 29 Dec 2016 Novartis has a published patent application with World Intellectual Property Organization for anti-factor XI antibodies or fragments for Thrombosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top